Traws Pharma, INC

Traws Pharma received a notification from Nasdaq regarding its non-compliance with the minimum bid price requirement, with 180 days to regain compliance.

Traws Pharma, Inc. has filed a Form 8-K detailing an At-The-Market (ATM) offering of up to $5,575,709 in common stock, pursuant to an effective shelf registration statement.

Traws Pharma, Inc. announced that its stockholders approved an amendment to the 2021 Incentive Compensation Plan, increasing available shares by 2 million and making administrative changes.

Traws Pharma has deferred its Phase 2a human influenza challenge study for tivoxavir marboxil following a negative regulatory review by the UK's MHRA.

Traws Pharma announces advancement of a novel broad-spectrum antiviral agent targeting Hantavirus, Ebola, and Lassa virus outbreaks.

Traws Pharma, Inc. has filed an 8-K detailing an update to its At-The-Market (ATM) offering, with a new prospectus supplement dated May 22, 2026, allowing for the sale of up to $3,128,399 in common stock.

Traws Pharma reported a significant increase in R&D expenses for Q1 2026, alongside a continued net loss and concerns about its ability to continue as a going concern.

Traws Pharma reports a net income for the nine months ended September 30, 2025, but faces substantial doubt about its ability to continue as a going concern due to limited cash reserves.

Traws Pharma, a clinical-stage biopharmaceutical company, reported a net income of $20.6 million for the first half of 2025, driven by warrant revaluation and deferred revenue recognition, despite ongoing operating losses and a going concern warning.

Traws Pharma reports a net income of $21.49 million for Q1 2025, primarily driven by changes in warrant liability, but expresses substantial doubt about its ability to continue as a going concern due to insufficient cash.

Traws Pharma's Q3 2024 results reveal a significant net loss driven by a large in-process R&D expense, alongside ongoing concerns about the company's ability to continue as a going concern.

Traws Pharma reports a significant net loss for the second quarter of 2024, driven by a large in-process R&D expense related to the acquisition of Trawsfynydd Therapeutics, and expresses substantial doubt about its ability to continue as a going concern.

Traws Pharma, Inc. filed an amendment to its 2025 Annual Report to provide required Part III corporate governance and executive compensation disclosures.

Traws Pharma, Inc. filed its annual report for the fiscal year ended December 31, 2025, detailing progress in its viral disease and oncology programs, alongside financial performance and future outlook.

Traws Pharma files an amendment to its 2024 annual report to include information previously omitted regarding directors, executive officers, and corporate governance.

Traws Pharma's 2024 10-K reveals a year of transformation through a merger, pipeline advancement, and ongoing financial uncertainties.

Traws Pharma has filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

Onconova Therapeutics' 10-K filing details the company's ongoing clinical trials and financial status, highlighting the development of narazaciclib and rigosertib for cancer treatment.

Charles David Pauza, Chief Science Officer Virology of Traws Pharma, Inc., received 97,000 shares of common stock on July 9, 2026.

Werner Cautreels, a Director of Traws Pharma, Inc., received 14,150 shares of common stock on July 9, 2026.

Nikolay Savchuk, Chief Operating Officer and a Director of Traws Pharma, Inc., received 93,000 shares of common stock on July 9, 2026.

Jack E Stover, a Director of Traws Pharma, Inc., received 14,150 shares of common stock on July 9, 2026.

Iain D. Dukes, Chief Executive Officer and a Director of Traws Pharma, Inc., received 274,000 shares of common stock on July 9, 2026.

Robert Redfield, Chief Medical Officer of Traws Pharma, Inc., received 84,000 shares of common stock on July 9, 2026.

Traws Pharma, Inc. has issued its 2026 proxy statement detailing director elections, equity plan amendments, and capital raise approvals.

TRAWS PHARMA, INC. announces details for its 2025 Annual Meeting, including proposals for director elections, compensation plan amendments, and auditor ratification.

Traws Pharma, Inc. announces its 2025 Annual Meeting of Stockholders to address director elections, an amended incentive plan, executive compensation, and auditor ratification.

Traws Pharma is holding a special meeting of stockholders to approve the issuance of common stock upon the exercise of warrants issued in a recent private placement, aiming to comply with Nasdaq listing requirements.

Traws Pharma is holding its 2024 Annual Meeting of Stockholders virtually on October 31, 2024, to vote on key proposals including director elections, an incentive compensation plan amendment, executive compensation, and auditor ratification.

Traws Pharma is holding a special meeting to seek stockholder approval for proposals including the issuance of shares upon conversion of preferred stock, an increase in authorized common stock, and a reverse stock split.

OrbiMed Advisors and OrbiMed Capital GP VIII have disclosed an increased beneficial ownership stake in Traws Pharma, Inc. following a recent private placement.

OrbiMed Advisors and OrbiMed Capital GP VIII LLC have increased their beneficial ownership in Traws Pharma, Inc. to 19.9% of outstanding common stock following the company's recent Class A and Class B Unit offering.

Ikarian Capital, LLC and Neil Shahrestani have jointly filed a Schedule 13G, reporting beneficial ownership of 9.5% of Traws Pharma, Inc.'s common stock, including shares issuable upon warrant exercise.

Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have reported zero beneficial ownership of Traws Pharma, Inc. common stock.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Traws Pharma, Inc. common stock.

Adage Capital Management, L.P. has disclosed a beneficial ownership of 730,000 shares, representing 4.79% of Traws Pharma, Inc.'s common stock, as of June 30, 2026.

Perceptive Advisors LLC and Joseph Edelman have reported a 6.1% beneficial ownership stake in Traws Pharma, Inc. through warrant holdings.

Squadron Master Fund LP, along with affiliated entities and individuals, has reported beneficial ownership of 511,714 shares, representing 6.4% of Traws Pharma, Inc.'s common stock.